Price (delayed)
$0.9029
Market cap
$264.43M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.55
Enterprise value
$245.46M
Precigen is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases
There are no recent dividends present for PGEN.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.